Eli Lilly and Company (LLY) Thursday reported topline data from Phase 3 ACHIEVE-1 study of orforglipron in adults with type 2 diabetes. The study met its primary goal.
ACHIEVE-1 is the first of seven Phase 3 studies evaluating the safety and efficacy of orforglipron across people with diabetes and obesity. The primary goal of the study was A1C reduction compared to placebo.
Treatment with orforglipron reduced A1C by an average of 1.3% to 1.6% across doses. The drug candidate also reduced weight by an average 16 lbs at the highest dose.
Later this year, the company plans to share more results from the ACHIEVE Phase 3 program as well as data from ATTAIN Phase 3 study evaluating orforglipron for weight management.
Lilly expects to submit orforglipron for weight management to global regulatory agencies by the end of this year, with the submission for the treatment of type 2 diabetes anticipated in 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.